Development and Validation of a Fourfold Multiplexed Opsonization Assay (MOPA4) for Pneumococcal Antibodies

ABSTRACT Opsonophagocytic killing assays (OPAs) are essential for developing and improving pneumococcal vaccines. There is a need for a high-throughput, reliable, standardized, and fully characterized OPA for pneumococcal antibodies. To meet the need, we have developed and characterized a fourfold multiplexed OPA (MOPA4) against 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) of pneumococci. Thirteen target bacteria were made resistant to only one of the following antibiotics: optochin, streptomycin, spectinomycin, and trimethoprim. Following optimization of assay conditions, accuracy of MOPA4 was determined by testing 30 sera from old adults in the MOPA4 and the single-serotype assays. The opsonization titers obtained with both assays agreed well (r2 > 0.95). Although 22 (out of 390; ∼6%) results differed more than twofold, the differences were not reproducible. The assay was specific: preabsorbing test sera with homologous polysaccharide (PS) completely abrogated opsonic activity, but a pool of unrelated PS (5 μg/ml of each) had no effect. Intra- and interassay coefficients of variation were 10 and 22%, respectively. MOPA4 results were unaffected by having different target pneumococcal serotypes in each assay group. Also, HL60 cell-to-bacteria ratios could be varied twofold without affecting the results. We conclude that MOPA4 is sensitive, accurate, specific, precise, and robust enough for large-scale clinical studies. Furthermore, MOPA4 should allow evaluation of multivalent pneumococcal vaccines with the limited volume of serum typically available from young children.

[1]  J. Rubins,et al.  Determination of Antibody Responses of Elderly Adults to All 23 Capsular Polysaccharides after Pneumococcal Vaccination , 1999, Infection and Immunity.

[2]  D. Briles,et al.  Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae , 1981, The Journal of experimental medicine.

[3]  S. Romero-Steiner,et al.  Evaluation of Multiplex Flow Cytometric Opsonophagocytic Assays for Determination of Functional Anticapsular Antibodies to Streptococcus pneumoniae , 2006, Clinical and Vaccine Immunology.

[4]  I. Jónsdóttir,et al.  An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. , 2000, Journal of clinical microbiology.

[5]  S. Romero-Steiner,et al.  Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. , 1999, Infection and immunity.

[6]  D. Briles,et al.  Effects of PspA and Antibodies to PspA on Activation and Deposition of Complement on the Pneumococcal Surface , 2004, Infection and Immunity.

[7]  G. Bruyn.  Pneumococcal vaccine , 2017, Reactions Weekly.

[8]  D. Briles,et al.  Development of a multi-specificity opsonophagocytic killing assay. , 2000, Vaccine.

[9]  Steven Black,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The Journal of pediatrics.

[10]  S. Black,et al.  Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. , 1999, The Pediatric infectious disease journal.

[11]  C. Frasch,et al.  Estimation of Group B Streptococcus Type III Polysaccharide-Specific Antibody Concentrations in Human Sera Is Antigen Dependent , 1998, Infection and Immunity.

[12]  M. Rennels,et al.  Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 in United States Infants , 1998, Pediatrics.

[13]  I. Jónsdóttir,et al.  Enzyme-Linked Immunosorbent Assay for Quantitation of Human Antibodies to Pneumococcal Polysaccharides , 2003, Clinical Diagnostic Laboratory Immunology.

[14]  R. Fleck,et al.  Use of HL-60 Cell Line To Measure Opsonic Capacity of Pneumococcal Antibodies , 2005, Clinical Diagnostic Laboratory Immunology.

[15]  Sally A. Quataert,et al.  Approach to Validating an Opsonophagocytic Assay for Streptococcus pneumoniae , 2005, Clinical Diagnostic Laboratory Immunology.

[16]  Sandra Romero-Steiner,et al.  Use of Opsonophagocytosis for Serological Evaluation of Pneumococcal Vaccines , 2006, Clinical and Vaccine Immunology.

[17]  R. de Groot,et al.  Multiplex opsonophagocytosis assay (MOPA): a useful tool for the monitoring of the 7-valent pneumococcal conjugate vaccine. , 2004, Vaccine.

[18]  R. Steele.  Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 in United States Infants , 1998, Clinical pediatrics.

[19]  S. Black,et al.  Efficacy of pneumococcal conjugate vaccines in large scale field trials , 2000, The Pediatric infectious disease journal.

[20]  M. Nahm,et al.  Efficiency of a Pneumococcal Opsonophagocytic Killing Assay Improved by Multiplexing and by Coloring Colonies , 2003, Clinical Diagnostic Laboratory Immunology.

[21]  David Goldblatt,et al.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. , 2003, Vaccine.

[22]  J. C. Parke,et al.  Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. , 1983, The Journal of infectious diseases.

[23]  A E Fiore,et al.  Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  J. Whitin,et al.  Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells , 1997, Clinical and diagnostic laboratory immunology.